Hysterectomy in India and UAE | Complete Patient Guide

• ELIGIBLE CONDITIONS (Primary Indications):

• Symptomatic uterine leiomyomas (fibroids) causing menorrhagia, bulk symptoms, or urinary compression, refractory to GnRH agonist therapy (e.g., leuprolide acetate), selective progesterone receptor modulators (e.g., ulipristal acetate), or uterine artery embolization

• Adenomyosis with debilitating dysmenorrhea and menorrhagia unresponsive to levonorgestrel-releasing IUD (Mirena), combined oral contraceptives, or endometrial ablation

• Endometriosis (Stage III–IV) with significant uterine involvement not amenable to repeat excisional surgery

• Uterine prolapse (POP-Q Stage III–IV) where uterine preservation is not desired or surgically feasible

• Endometrial hyperplasia with atypia (high risk of progression to carcinoma) or confirmed endometrial carcinoma (FIGO Stages I–III)

• Cervical carcinoma (early-stage, requiring radical hysterectomy with pelvic lymph node dissection)

• Chronic pelvic pain with confirmed uterine etiology, refractory to multidisciplinary pain management

• Postpartum hemorrhage or uterine rupture unresponsive to conservative measures (emergency indication)

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Transvaginal ultrasound (TVUS) and pelvic MRI (3T preferred) for uterine mapping, fibroid burden assessment, and deep infiltrating endometriosis staging

• Endometrial biopsy (Pipelle sampling) or hysteroscopy-directed biopsy to exclude endometrial malignancy

• Cervical Pap smear and HPV co-testing

• Full blood count (FBC), coagulation profile (PT/INR/aPTT), renal and liver function tests, HbA1c (if diabetic)

• CA-125, HE4, and ROMA score calculation (if ovarian pathology or malignancy is suspected)

• PET-CT scan (for confirmed gynecologic malignancy staging)

• Electrocardiogram (ECG) and transthoracic echocardiogram (ECHO) for patients over 50 or with cardiac history

• Anesthesiology pre-assessment including airway evaluation and ASA physical status classification

• DVT risk stratification using the Caprini Risk Assessment Model

• CONTRAINDICATIONS & RELATIVE CONTRAINDICATIONS:

• Active pelvic or systemic infection (must be treated and resolved prior to elective surgery)

• Uncorrected coagulopathy or anticoagulation that cannot be safely bridged

• Uncontrolled diabetes (HbA1c >8.5%) or severe cardiopulmonary disease (ASA Class IV) without pre-optimization

• Desire for future pregnancy (hysterectomy is irreversible; alternatives such as myomectomy or endometrial ablation must be fully discussed and declined)

• Morbid obesity (BMI >45) may require dedicated bariatric pre-optimization prior to elective hysterectomy, though robotic assistance partially mitigates laparoscopic technical difficulty in obese patients

SURGICAL APPROACHES — FROM LEAST TO MOST INVASIVE:

1. TOTAL LAPAROSCOPIC HYSTERECTOMY (TLH) — Gold Standard for Benign Disease

The uterus and cervix are removed entirely through 3–4 small (5–12 mm) abdominal ports. The vaginal cuff is sutured laparoscopically or vaginally. Operative time: 60–120 minutes. Estimated blood loss: 50–150 mL. Hospital stay: 1–2 nights. Return to light activity: 2 weeks. This approach is preferred for uteri up to 14 weeks' gestational size in the absence of extensive adhesions.

2. ROBOT-ASSISTED LAPAROSCOPIC HYSTERECTOMY (RALH) — da Vinci Si/Xi System

Indicated for complex benign disease (large fibroids, severe endometriosis with frozen pelvis, prior pelvic surgeries with dense adhesions) and early-stage gynecologic malignancy. The robotic platform provides 10× magnification, EndoWrist articulation, and the surgeon's tremor is filtered electronically. In oncologic RALH, sentinel lymph node (SLN) mapping using Firefly ICG fluorescence technology allows real-time lymphatic identification, reducing the extent of lymphadenectomy and associated lymphedema risk. Hospital stay: 2–3 nights. Return to activity: 2–3 weeks.

3. VAGINAL HYSTERECTOMY (VH)

The uterus is removed entirely through a vaginal incision with no abdominal skin incisions. The approach of choice for uterine prolapse (with or without concurrent pelvic floor repair — anterior/posterior colporrhaphy, sacrospinous ligament fixation). The absence of abdominal wounds results in minimal post-operative pain and the fastest recovery. Not suitable for large uteri, suspected malignancy, or significant adnexal pathology.

4. LAPAROSCOPIC-ASSISTED VAGINAL HYSTERECTOMY (LAVH)

A hybrid approach where laparoscopy assists in the upper dissection (particularly the adnexal pedicles) and the specimen is delivered vaginally. Useful when vaginal access is technically suitable but laparoscopic control of the upper pedicles is advantageous.

5. TOTAL ABDOMINAL HYSTERECTOMY (TAH) — Open Surgery

Midline vertical or Pfannenstiel (horizontal bikini-line) incision. Reserved for very large uteri (>20 weeks gestational size), cases where laparoscopic conversion is required due to hemorrhage or dense adhesions, or in resource-limited intraoperative circumstances. Associated with longer hospital stays (3–5 nights), greater analgesic requirements, higher wound complication rates, and longer recovery (4–6 weeks). Increasingly performed only when minimally invasive approaches are contraindicated.

6. RADICAL HYSTERECTOMY (WERTHEIM'S / MODIFIED RADICAL — TYPE II or III)

Performed for cervical carcinoma (FIGO Stages IA2–IIA) and selected endometrial carcinoma cases. Involves en bloc removal of the uterus, cervix, parametrium, upper vagina (1–2 cm cuff), and systematic pelvic lymphadenectomy (obturator, external and internal iliac, common iliac nodes). Para-aortic lymph node sampling may be added. Now routinely performed robotically at top centers, replacing the traditional open approach. Intraoperative ureteral stenting and nerve-sparing modifications (Type III-NS) reduce the rates of bladder dysfunction, urinary retention, and ureterovaginal fistula.

7. SUBTOTAL (SUPRACERVICAL) HYSTERECTOMY

The uterine body is removed while the cervix is retained. Rarely chosen due to the need for continued cervical cancer screening and minimal evidence of superior sexual function outcomes compared to total hysterectomy. Performed laparoscopically (LASH — Laparoscopic Supracervical/Subtotal Hysterectomy) using a morcellator in contained-bag systems to minimize dissemination risk.

ADJUNCT TECHNOLOGIES:

• Contained power morcellation with in-bag systems (for specimen extraction in laparoscopic fibroid cases)

• Ureteric stent placement under cystoscopy to prevent ureteral injury in complex dissections

• Intraoperative cell salvage (autotransfusion) in cases with anticipated significant blood loss

• Enhanced Recovery After Surgery (ERAS) protocols: multimodal opioid-sparing analgesia (IV acetaminophen, ketorolac, dexamethasone, transversus abdominis plane — TAP — block), early oral intake, early ambulation, pneumatic compression devices for DVT prophylaxis

PRE-OPERATIVE PHASE (Weeks 1–3 Before Surgery):

Step 1 — Remote Consultation & Case Review: The patient submits her medical records, imaging (TVUS, pelvic MRI, pathology reports), and blood work to GAF Healthcare. A GAF-affiliated gynecologist or gynecologic oncologist conducts a video consultation to confirm diagnosis, discuss surgical approach, and estimate operative complexity. A detailed treatment plan, itemized cost estimate, and provisional surgery date are issued within 48 hours.

Step 2 — Pre-Travel Optimization: Patients with iron-deficiency anemia (common with fibroids/menorrhagia) are commenced on IV iron infusion (ferric carboxymaltose) or oral iron supplementation 3–6 weeks pre-operatively to optimize hemoglobin (target Hb ≥11 g/dL). Anticoagulants (warfarin, DOACs) are bridged per hematology guidance. GnRH agonist therapy (e.g., monthly leuprolide depot) may be prescribed for 2–3 months to reduce uterine volume and control hemorrhage pre-operatively in fibroid cases.

Step 3 — Arrival & Pre-Admission Workup (Days 1–2 In-Country): GAF arranges airport pickup and hotel/accommodation check-in. The patient attends the hospital for a full pre-operative work-up: complete blood count, coagulation screen, metabolic panel, ECG, anesthesiology assessment, and surgical consent documentation. Bowel prep (if required), skin preparation guidance, and nil-by-mouth instructions are issued.

INTRA-OPERATIVE PHASE (Day 3 — Surgery Day):

Step 4 — Surgery: Under general anesthesia (total intravenous anesthesia — TIVA — or balanced inhalational technique with LMA or endotracheal tube), the procedure is performed as planned (TLH, RALH, VH, or radical). Average operative times: TLH/RALH: 60–150 minutes; Radical hysterectomy: 2.5–4 hours. Uterine specimen is sent for histopathological examination intraoperatively (frozen section) and definitively (paraffin section, results in 5–7 days). A urethral catheter is placed intraoperatively and typically removed within 12–24 hours for minimally invasive cases.

POST-OPERATIVE PHASE — IN-HOSPITAL RECOVERY (Days 3–5):

Step 5 — Immediate Recovery (0–24 hours post-op): Patient is managed in the recovery suite, then transferred to a private ward. ERAS protocol is activated: early sips of clear fluids at 2 hours, light diet at 6 hours, first ambulation (with physiotherapist assistance) at 8–12 hours. Pain managed with scheduled IV paracetamol, NSAIDs (ketorolac), and low-dose opioids (tramadol/morphine) as rescue. Sequential compression devices maintained for DVT prophylaxis. Low-molecular-weight heparin (LMWH, e.g., enoxaparin 40 mg SC daily) commenced 6–12 hours post-operatively.

Step 6 — Days 1–2 Post-Op: Catheter removal, confirmation of spontaneous voiding, transition to oral analgesia (diclofenac + paracetamol ± pregabalin for nerve pain). Wound check for laparoscopic port sites. Drain removal (if placed). Discharge planning initiated. Pathology results discussed once available.

POST-OPERATIVE PHASE — OUTPATIENT RECOVERY (Days 5–28):

Step 7 — Immediate Post-Discharge (Days 3–14): Patient remains in the country, accommodated in a GAF-partner hotel or serviced apartment. GAF nurse coordinator conducts daily check-in calls. Activity guidelines: short walks encouraged (prevents DVT), no lifting >3 kg, no sexual intercourse, no bathing in pools or bathtubs (shower only), no driving. Pelvic rest continues for 6–8 weeks (until vaginal cuff heals confirmed on follow-up).

Step 8 — Surgical Follow-Up Appointment (Day 10–14): In-person review with the operating surgeon. Wound inspection, vaginal cuff assessment (via speculum), LMWH cessation (typically day 28 post-surgery, or as prescribed for oncologic cases). Final pathology results reviewed and communicated. Fit-to-fly assessment performed: for minimally invasive hysterectomy, most patients are cleared for a long-haul flight at 2 weeks; for radical hysterectomy or complex open surgery, 3–4 weeks is standard due to increased DVT risk in immobile flight conditions.

Step 9 — Long-Term Recovery Milestones:

• Return to desk work: 2 weeks (minimally invasive); 4–6 weeks (open)

• Return to driving: 2–3 weeks (minimally invasive); 4–6 weeks (open, or when able to perform emergency braking without pain)

• Return to full physical activity / exercise: 6–8 weeks

• Vaginal cuff fully healed (confirmed on exam): 6–8 weeks

• Hormone replacement therapy (HRT) initiated (if bilateral oophorectomy performed): Day 1–2 post-op (estrogen-only patch or gel, e.g., estradiol 50–100 mcg/24h transdermal)

• Oncology follow-up: outpatient plan for CT chest/abdomen/pelvis at 3 months, 6 months, and annually for 5 years (for malignant indications); coordinated with GAF telemedicine follow-up and the patient's home oncologist